Market capitalization | $1.25b |
Enterprise Value | $1.23b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 41.63 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-46.13m |
Free Cash Flow (TTM) Free Cash Flow | $-35.54m |
Cash position | $26.20m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
1 Analyst has issued a forecast Pulse Biosciences, Inc.:
1 Analyst has issued a forecast Pulse Biosciences, Inc.:
Jun '24 | |
Current assets | 27 27 |
Fixed assets | 13 13 |
Total Assets | 40 40 |
Jun '24 | |
Equity | 27 27 |
Debt capital | 13 13 |
Total Capital | 40 40 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
Head office | United States |
CEO | Burke Barrett |
Employees | 56 |
Founded | 2014 |
Website | www.pulsebiosciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.